Digital chronic care company Omada has announced its first profitable quarter since going public less than a year ago, revealing this milestone alongside its full-year 2025 earnings. The company reported a revenue of $260 million for 2025, reflecting a 53% increase over the previous year and surpassing earlier projections made at the J.P. Morgan Healthcare Conference.
Omada’s financial success comes as it strategically positions itself to leverage the growing demand for GLP-1 obesity medications. The company has also provided optimistic earnings guidance for 2026, indicating a sustained growth trajectory. This profitability not only marks a significant achievement for Omada but also highlights the increasing importance of digital health solutions in the pharmaceutical landscape, particularly in chronic disease management.
As the market for GLP-1 medications expands, Omada’s success could serve as a benchmark for other digital health companies aiming to navigate the complexities of profitability in a competitive environment.
Open the full market picture for your next decision →
